Articles related to PEER-TO-PEER

Most people would agree that a doctor’s behavior is unprofessional, arguably unethical, and certainly unacceptable when he or she uses the wrong treatment, whether willfully or through ignorance, or when they use the right treatment incorrectly. What, then, should we think about researchers who use the wrong techniques, use the right techniques wrongly, misinterpret their results, report their results selectively, cite the literature selectively, and draw unjustified conclusions?

Not surprisingly, given the rate at which new FDA approvals are granted, the majority of clinicians prescribed a newly FDA-approved drug in the previous year, with 20% prescribing at least ten new drugs, according to OBRs Oncology Drug Report 2022. The latter metric demonstrates how quickly the world of cancer care is evolving, which has a number of important implications for oncology practice.

A reflective case study highlights this author’s take on papillary thyroid cancer, which has high survivability but cannot be considered “good.” Telling patients they have good cancer is dismissive and minimizes the patient experience associated with this diagnosis. When caring for patients with papillary thyroid cancer, this commonly used statement is contradictory. Providers of all specialties must consider the psychological and physiological effects that papillary thyroid cancer has on patients. It is critical to practice improving news delivery through effective and empathetic communication.

Anthony Fauci, MD, reflects on the surprising and dramatic challenges faced by a medical specialty that was in the 1960s and up to the late ’70s predicted to be destined for obsolescence.

This physician relates his struggle with drinking that was mostly “internal, with few external consequences” as he puts it — just a few occasional red lights as he looked at how his alcohol use was touching his relationships with himself, his wife, and his kids.

Genetic tools such as CRISPR could enable creating a close approximation Neanderthal or other lost species DNA. Harvard geneticist George Church, PhD, argued some potential benefits to humans. But what are the potential implications and how should the question be weighed?